Sign inJoin waitlistJoin the waitlist

Marissa Botwinick

Assistant Professor · Rutgers Health

Credentials: · · · ·

History

Rutgers Health
Present

New York Medical College
2022–2023
Pediatric Hematology/Oncology
Westchester Medical Center
2019–2022
Pediatrics
2016–2019
Touro Univ of Nevada Coll of Osteo Med
2012–2016

Research

Ventriculomegaly and cerebellar hypoplasia in a neonate with interstitial 11q 24 deletion in Jacobsen syndrome region
Case report · Clinical Case Reports · 2018 · 5 citations
Biliary Tract Abnormalities as a Cause of Distal Bowel Gas in Neonatal Duodenal Atresia
Case report · Case Reports in Surgery · 2018 · 2 citations
Pernicious Anemia in a Pediatric Patient With Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy
Case report · JCEM Case Reports · 2025

Charlotte Chen
2 papers · 2 as a resident
RM
Rajeev Mehta
2 papers
SP
Surasak Puvabanditsin
2 papers
AP
Andrew Parrott
1 paper
BM
Bethany Murphy
1 paper · 1 as a fellow
DeAnna Diaz
1 paper · 1 as a resident
Fahmida Islam
1 paper
JM
Joseph Mariduena
1 paper · 1 as a fellow
KH
Karen Hussein
1 paper · 1 as a fellow
KB
Katherine Briski
1 paper · 1 as a fellow
KK
Konstandina Kokinakos
1 paper · 1 as a resident
MR
Maya Ramagopal
1 paper

Clinical trials

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2028
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Site PI · Recruiting · Phase 3
Children's Oncology Group
2020–2029